rofecoxib has been researched along with Heart Failure in 19 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "We tested the time to signal detection of quantitative ADR signalling methods in a health claims database (SSA) and in a spontaneous reporting database (ROR, PRR, Bayesian confidence propagation neural network) for rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure." | 7.80 | Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. ( A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE, 2014) |
| "The case of a 59-year-old healthy woman is described, who developed an extreme sinus bradycardia (30/min) with chest pain and acute right heart failure associated with gastrointestinal symptoms and elevation of the liver enzymes while simultaneously taking tizanidine (Sirdalud), diclofenac (Voltaren), and rofecoxib (Vioxx)." | 7.73 | [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)]. ( Bertoli, R; Caduff Janosa, P; Cerny, A; Kick, A; Moschovitis, G, 2005) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 7.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "We tested the time to signal detection of quantitative ADR signalling methods in a health claims database (SSA) and in a spontaneous reporting database (ROR, PRR, Bayesian confidence propagation neural network) for rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure." | 3.80 | Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. ( A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE, 2014) |
| "Nonsteroidal antiinflammatory drugs (NSAIDs) as a class have been shown to increase the risk of congestive heart failure (CHF) compared with celecoxib." | 3.74 | Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? ( Hudson, M; Pilote, L; Rahme, E; Richard, H, 2007) |
| "The case of a 59-year-old healthy woman is described, who developed an extreme sinus bradycardia (30/min) with chest pain and acute right heart failure associated with gastrointestinal symptoms and elevation of the liver enzymes while simultaneously taking tizanidine (Sirdalud), diclofenac (Voltaren), and rofecoxib (Vioxx)." | 3.73 | [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)]. ( Bertoli, R; Caduff Janosa, P; Cerny, A; Kick, A; Moschovitis, G, 2005) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 3.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls." | 3.72 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA, 2004) |
| "To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." | 3.71 | Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. ( Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ, 2002) |
| " Inhibition of COX-2 has been associated with the therapeutic effects of NSAIDs, whereas inhibition of COX-1 is believed to be the cause of the adverse gastrointestinal effects associated with NSAID therapy." | 1.31 | A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. ( Arellano, FM; Lejkowith, J; Reynolds, MW; Whelton, A; Zhao, SZ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (78.95) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| A Wahab, I | 1 |
| Pratt, NL | 1 |
| Kalisch, LM | 1 |
| Roughead, EE | 1 |
| Ungprasert, P | 1 |
| Srivali, N | 1 |
| Kittanamongkolchai, W | 1 |
| Streicher, JM | 1 |
| Kamei, K | 1 |
| Ishikawa, TO | 1 |
| Herschman, H | 1 |
| Wang, Y | 1 |
| Mintzes, B | 1 |
| Mangin, D | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Whelton, A | 3 |
| White, WB | 1 |
| Bello, AE | 1 |
| Puma, JA | 1 |
| Fort, JG | 1 |
| Zhao, SZ | 2 |
| Burke, TA | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| SoRelle, R | 1 |
| Mamdani, M | 1 |
| Juurlink, DN | 1 |
| Lee, DS | 1 |
| Rochon, PA | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Stukel, TA | 1 |
| García Nicolás, FJ | 1 |
| Kick, A | 1 |
| Bertoli, R | 1 |
| Moschovitis, G | 1 |
| Caduff Janosa, P | 1 |
| Cerny, A | 1 |
| Hudson, M | 2 |
| Richard, H | 2 |
| Pilote, L | 2 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Rahme, E | 1 |
| McGettigan, P | 1 |
| Han, P | 1 |
| Jones, L | 1 |
| Whitaker, D | 1 |
| Henry, D | 1 |
| Ofran, Y | 1 |
| Bursztyn, M | 1 |
| Ackerman, Z | 1 |
| Reynolds, MW | 1 |
| Lejkowith, J | 1 |
| Arellano, FM | 1 |
3 reviews available for rofecoxib and Heart Failure
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progression; Heart Failure; Humans; Lact | 2015 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
1 trial available for rofecoxib and Heart Failure
| Article | Year |
|---|---|
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
15 other studies available for rofecoxib and Heart Failure
| Article | Year |
|---|---|
Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia.
Topics: Adverse Drug Reaction Reporting Systems; Australia; Bayes Theorem; Cyclooxygenase 2 Inhibitors; Data | 2014 |
Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice.
Topics: Animals; Cardiomegaly; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Heart Failure; Heart Ventricle | 2010 |
Direct-to-consumer advertising of prescription medicines: a counter argument.
Topics: Advertising; Drug Prescriptions; Heart Failure; Lactones; Power, Psychological; Public Health; Sulfo | 2009 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2002 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
Rofecoxib use increases acute myocardial infarction risk.
Topics: Aortic Aneurysm, Abdominal; Benzazepines; Cardiology; Cholesterol; Female; Heart Failure; Humans; La | 2004 |
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; | 2004 |
[Probable cardiac failure due to rofecoxib].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Female; Follow-Up Studies; | 2005 |
[Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Bradycardia; Clonidine; Cyclooxy | 2005 |
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Celecoxib; Cohort Studies; Cyclooxyge | 2005 |
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2007 |
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Fibrosis; Heart Fa | 2001 |
A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Topics: Acute Kidney Injury; Angiotensin Amide; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxy | 2001 |